Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Hot Stocks Free for All !
»
DNDN * $4.40 --FDA approval letter possible next week--more>>
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by Jo4321: [QB] Monday, April 02, 2007 4:46:59 PM ET JMP Securities NEW YORK, April 2 (newratings.com) - Analysts at JMP Securities reiterate their "strong buy" rating on Dendreon Corp (DNR.FSE), while revising their estimates for the company. The target price has been raised from $12 to $20. In a research note published on March 30, the analysts mention that Center for Biologics Evaluation and Research (CBER) panel has unanimously voted in favour of the safety and efficacy of the company’s Provenge’s BLA for the treatment of late-stage prostate cancer. The analysts believe that the FDA would grant Dendreon an approvable letter for Provenge going forward. The EPS estimate for FY07 has been reduced from -$0.49 to -$1.15. The EPS estimate for FY10 has been raised from $0.84 to $1.27. [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2